

**STATE FUNDING**

# **MCKINSEY SETTLEMENT & MEDICAL MARIJUANA REVENUE**

## **MCKINSEY SETTLEMENT**

As a result of legal action brought by the Commonwealth against McKinsey and Company, Inc., a final consent judgement ordered that the Department of Drug and Alcohol Programs (DDAP) will receive \$25.7 million to be used by DDAP or its designees or grantees to fund opioid use disorder treatment and abatement programs.

## **MEDICAL MARIJUANA REVENUE**

Act 16 of 2016 requires ten percent of the revenue in the Medical Marijuana Program fund to be allocated to the Department of Drug and Alcohol Programs for substance use disorder (SUD) prevention, counseling and treatment services.

## **STRENGTHEN THE DRUG AND ALCOHOL TREATMENT SYSTEM**

### **STUDENT LOAN REPAYMENT - \$10 MILLION - MCKINSEY SETTLEMENT & MEDICAL MARIJUANA REVENUE**

In an effort to support and stabilize the substance use disorder workforce, \$5 million from the McKinsey opioid settlement and \$5 million from the Medical Marijuana revenue fund will be directed toward a student loan repayment program to be administered by DDAP beginning in SFY 2021/2022.

Clinical and medical personnel from DDAP-licensed treatment providers as well as individuals providing Single County Authority (SCA) or SCA-contracted case management services will be eligible to apply for these funds. Selected candidates must demonstrate a minimum of two prior years of experience in the SUD field as well as agree to a service commitment of two additional years.

This report is accurate as of December 2021; program development and procurement are ongoing.